BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,070 filers reported holding BAXTER INTL INC in Q3 2021. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2023 | $251,290 | +2.4% | 6,500 | 0.0% | 0.02% | -8.7% |
Q3 2023 | $245,375 | -17.1% | 6,500 | 0.0% | 0.02% | -11.5% |
Q2 2023 | $296,140 | +12.3% | 6,500 | 0.0% | 0.03% | +8.3% |
Q1 2023 | $263,640 | -20.5% | 6,500 | -50.0% | 0.02% | -22.6% |
Q4 2022 | $331,636 | -5.2% | 13,000 | +100.0% | 0.03% | -11.4% |
Q3 2022 | $350,000 | -16.1% | 6,500 | 0.0% | 0.04% | -10.3% |
Q2 2022 | $417,000 | -18.6% | 6,500 | 0.0% | 0.04% | -2.5% |
Q1 2022 | $512,000 | -8.2% | 6,500 | 0.0% | 0.04% | -7.0% |
Q4 2021 | $558,000 | +6.7% | 6,500 | 0.0% | 0.04% | 0.0% |
Q3 2021 | $523,000 | -2.1% | 6,500 | 0.0% | 0.04% | 0.0% |
Q2 2021 | $534,000 | -2.6% | 6,500 | 0.0% | 0.04% | -8.5% |
Q1 2021 | $548,000 | +6.4% | 6,500 | 0.0% | 0.05% | -7.8% |
Q4 2020 | $515,000 | -0.4% | 6,500 | 0.0% | 0.05% | -15.0% |
Q3 2020 | $517,000 | -5.8% | 6,500 | 0.0% | 0.06% | -4.8% |
Q2 2020 | $549,000 | +2.8% | 6,500 | 0.0% | 0.06% | +1.6% |
Q1 2020 | $534,000 | -2.2% | 6,500 | 0.0% | 0.06% | +51.2% |
Q4 2019 | $546,000 | -3.9% | 6,500 | 0.0% | 0.04% | -6.8% |
Q3 2019 | $568,000 | +7.0% | 6,500 | 0.0% | 0.04% | +7.3% |
Q2 2019 | $531,000 | +0.4% | 6,500 | 0.0% | 0.04% | -4.7% |
Q1 2019 | $529,000 | +23.6% | 6,500 | 0.0% | 0.04% | +13.2% |
Q4 2018 | $428,000 | -14.1% | 6,500 | 0.0% | 0.04% | +2.7% |
Q3 2018 | $498,000 | +3.8% | 6,500 | 0.0% | 0.04% | -5.1% |
Q2 2018 | $480,000 | +15.7% | 6,500 | 0.0% | 0.04% | +11.4% |
Q1 2018 | $415,000 | -1.2% | 6,500 | 0.0% | 0.04% | +2.9% |
Q4 2017 | $420,000 | +3.4% | 6,500 | 0.0% | 0.03% | 0.0% |
Q3 2017 | $406,000 | +3.8% | 6,500 | 0.0% | 0.03% | -2.9% |
Q2 2017 | $391,000 | +15.0% | 6,500 | 0.0% | 0.04% | +16.7% |
Q1 2017 | $340,000 | +18.1% | 6,500 | 0.0% | 0.03% | +11.1% |
Q4 2016 | $288,000 | -6.8% | 6,500 | 0.0% | 0.03% | -15.6% |
Q3 2016 | $309,000 | +5.1% | 6,500 | 0.0% | 0.03% | +3.2% |
Q2 2016 | $294,000 | +9.7% | 6,500 | 0.0% | 0.03% | +6.9% |
Q1 2016 | $268,000 | +8.1% | 6,500 | 0.0% | 0.03% | +7.4% |
Q4 2015 | $248,000 | +15.9% | 6,500 | 0.0% | 0.03% | +12.5% |
Q3 2015 | $214,000 | -53.0% | 6,500 | 0.0% | 0.02% | -51.0% |
Q2 2015 | $455,000 | +2.2% | 6,500 | 0.0% | 0.05% | +4.3% |
Q1 2015 | $445,000 | -6.5% | 6,500 | 0.0% | 0.05% | -13.0% |
Q4 2014 | $476,000 | +1.9% | 6,500 | 0.0% | 0.05% | -3.6% |
Q3 2014 | $467,000 | -1.3% | 6,500 | 0.0% | 0.06% | -3.4% |
Q2 2014 | $473,000 | -1.0% | 6,500 | 0.0% | 0.06% | -10.8% |
Q1 2014 | $478,000 | +5.8% | 6,500 | 0.0% | 0.06% | -4.4% |
Q4 2013 | $452,000 | +5.9% | 6,500 | 0.0% | 0.07% | -6.8% |
Q3 2013 | $427,000 | -12.0% | 6,500 | -7.1% | 0.07% | -20.7% |
Q2 2013 | $485,000 | – | 7,000 | – | 0.09% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |